Preclinical models of breast cancer: b6bc, a transplantable hormone receptor-positive c57bl/6 mouse cell line

Abstract

Preclinical animal models are essential tools to develop and evaluate new anticancer treatments, notably immunotherapies, in which the complex interactions between cancer cells and the immune system need to be recapitulated. Consequently, the degree to which the preclinical model mimics certain disease aspects likely conditions its clinical translatability. In the context of breast cancer (BC), representative models should mimic key disease features such as the hormone receptor and ERBB2 status, as well as the composition of the tumor immune infiltrate. However, such information is generally limited notably for transplantable mouse cancer cell lines, which tend to be poorly characterized with respect to their histopathological subtype and to the tumor microenvironment that they generate, especially if they fail to strive after injection into syngeneic hosts [1].